Here we discussed the underlying working mechanisms of CEACAM5 in intestinal barrier dysfunction induced by SARS-Cov-2 spike, which may provide promising therapeutic targets for alleviating GI symptoms in COVID-19 patients and further enhance the treatment of SARS-Cov-2 infection. Here, CEACAM5 is linked to COVID-19.